Cancer Venous Thromboembolism (VTE)

Inclusion Criteria: * Male or female subjects with age ≥ 18 years or the otherwise legal lower age according to the country of residence; * Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated; * Cancer, other than basal-cell or squamous-cell carcinoma of the skin; * Able to provide written informed consent. Exclusion Criteria: * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE; * Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization; * Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban; * Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;